Volume 110, Issue s33

A better understanding and early identification of impaired fasting glucose will allow health care professionals to take a more comprehensive approach to multi-factorial diabetes management validated by published data and guidelines.

The metabolic syndrome increases the risk of CVD independent of the baseline risk from the usual CHD risk factors.

In the patient-centered medical home (PCMH) model of practice, MetSyn can be used as a marker for obese patients needing heightened attention to lifestyle and other interventions to reduce risk of adverse events.

The real value of diagnosing the metabolic syndrome may be to engender clinicians with a mind-set to focus on prevention of disease.